If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCraven House Capital Regulatory News (CRV)

  • This share is currently suspended. It was suspended at a price of 0.125
  • There is currently no data for CRV

Issue of Equity

16 Jun 2016 07:00

RNS Number : 3312B
Craven House Capital PLC
16 June 2016
 

16 June 2016

 

 

 Craven House Capital plc ("Craven House" or the "Company")

 

Cash placing of 266,828,899 new ordinary shares at 1.25 pence per share

 

Craven House Capital (AIM: CRV) announces that it has raised approximately £3.34 million in cash (before expenses), through a placing (the "Placing") of 266,828,899 new ordinary shares of 0.1p each in the Company ("Placing Shares") at a price of 1.25p per Placing Share ("Placing Price").

The net proceeds of the Placing will be used to further execute the Company's investment policy. A number of prospective investment opportunities in our target markets are currently under evaluation and further updates will be provided to the market in due course.

 

Further to previous announcements, the Company is continuing its discussions with additional prospective investors with regard to making investments in the Company via further subscriptions for new shares and updates will be provided to the market in due course.

 

Application will be made for the Placing Shares, which will rank pari passu with the existing ordinary shares in the Company, to be admitted to trading on AIM. It is expected that Admission will become effective and dealings will commence at 8.00 a.m. on 21 June 2016.

 

Following Admission the total issued share capital will consist of 1,349,781,519 ordinary shares. As such the total number of voting rights in the Company will be 1,349,781,519 ordinary shares. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

 

~ Ends ~

 

 

For further information please contact:

 

Craven House Capital Plc

Mark Pajak

www.Cravenhousecapital.com

 

Tel: 020 7002 1027

 

SI Capital

Broker

Nick Emerson

www.sicapital.co.uk

Tel: 01483 413500

 

SPARK Advisory Partners Limited

Nominated Adviser

Matt Davis/Mark Brady

www.Sparkadvisorypartners.com

 

Tel: 0203 368 3550

 

 

About Craven House Capital

Craven House Capital (AIM: CRV) is an investment company seeking deep value opportunities across the globe. It seeks to create long-term shareholder value on a per share basis by deploying patient capital. Craven House seeks to acquire real assets and operating companies that capable of generating steady cash flows.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEDELFFQQFFBBF
Date   Source Headline
24th Jul 20257:00 amRNSCancellation - Craven House Capital PLC
23rd Jun 202510:30 amRNSWithdrawl of 'Stmt re Share Price Movement' RNS
23rd Jun 202510:05 amRNSStatement re Share Price Movement
23rd Jun 20257:30 amRNSSuspension - Craven House Capital Plc
23rd Jun 20257:00 amRNSResignation of Nominated Adviser
27th Feb 20257:00 amRNSInterim Results
7th Feb 20254:22 pmRNSTR-1: Notification of major holdings
16th Dec 20242:42 pmRNSResult of AGM
15th Nov 20247:00 amRNSAnnual Results For Year Ended 31 May 2024
10th Sep 20247:00 amRNSInvestee company update: RoseMonkey Ltd
27th Aug 20247:00 amRNSTR-1: Notification of major holdings
23rd Aug 20242:19 pmRNSTR-1: notification of major holdings
5th Jun 20247:00 amRNSInvestee Companies' Update: Bio Vitos
28th Feb 20247:00 amRNSInterim Results
4th Jan 20247:00 amRNSResult of Annual General Meeting
29th Nov 20232:48 pmRNSAnnual Results for year ended 31 May 2023
28th Nov 20234:08 pmRNSInvestee Companies' Update
16th Nov 20239:07 amRNSInvestee Companies’ Update: Garimon and Honeydog
23rd Oct 20237:00 amRNSInvestee company update: Bio Vitos
17th Oct 20237:46 amRNSInvestee Companies’ Update: Garimon and Honeydog
29th Aug 20231:34 pmRNSInvestee company update: Bio Vitos
3rd Jul 20231:32 pmRNSInvestee company update: Bio Vitos
3rd Mar 20236:15 pmRNSPortfolio Update
27th Feb 20233:30 pmRNSInterim Results
8th Feb 20237:00 amRNSInvestee company update: Bio Vitos
27th Jan 202311:33 amRNSResult of Annual General Meeting
29th Nov 20227:00 amRNSAnnual Results for Year Ended 31 May 2022
15th Nov 20222:42 pmRNSInvestee company update: Garimon Ltd
23rd Feb 20223:01 pmRNSInterim Results
21st Jan 202212:45 pmRNSResult of AGM
23rd Dec 20213:59 pmRNSNotice of AGM
29th Nov 20216:29 pmRNSAnnual Results for year ended 31 May 2021
24th Nov 20212:55 pmRNSInvestee company update: OneBas.Com Ltd.
26th Oct 20217:00 amRNSInvestee company update: YRRO Ltd
16th Mar 20211:06 pmRNSTR-1: Notification of major holdings
18th Feb 20213:07 pmRNSInterim Results
11th Feb 202111:21 amRNSTR-1: Notification of major holdings
5th Feb 202110:44 amRNSStatement Regarding Share Price Movement
18th Jan 20212:49 pmRNSResult of Annual General Meeting
21st Dec 20207:00 amRNSNotice of General Meeting
9th Dec 20207:00 amRNSInvestee Company Update: YRRO Ltd
3rd Dec 202012:43 pmRNSAnnual Results for year ended 31 May 2020
9th Nov 20209:45 amRNSChange of Auditor
9th Oct 20203:14 pmRNSTrading Update, Change of Auditor & 2020 Results
18th Sep 202010:57 amRNSInvestee company update: Magazinos.com
22nd Jun 20201:01 pmRNSTR-1: Notification of major holdings
18th Jun 202011:06 amRNSSecond Price Monitoring Extn
18th Jun 202011:00 amRNSPrice Monitoring Extension
3rd Jun 20201:27 pmRNSTR-1: Notification of major holdings
1st Jun 20202:05 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.